PharmAust is continuing the recruitment of pet dogs in Australia, New Zealand and the United States with untreated B cell lymphoma to finalise the evaluation of a promising, newly formulated anti-cancer drug.
PharmAust’s drug Monepantel (MPL) has demonstrated effective anti-cancer activity and minimal side effects in the latest Phase 2 trials of pet dogs with untreated B-cell lymphoma.
Further recruitment of pet dogs with untreated B cell lymphoma will allow a successful Phase 2 evaluation to be completed, and lead to the commencement of a subsequent Phase 3 registration trial.
For information on all the current trial centres and trial entry criteria, please visit www.pharmaust.com/petdogtrial